Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
otherwise indicated.
Financial Highlights
Strong financial position with $433.5 million in cash and marketable securities.
Maintained #1 leadership position in Canada with 8.3% cannabis market share.
Beverage-alcohol sales increased 56% to $21.4 million, over the prior year quarter, including revenue from acquisitions.
Gross profit rose to $40.1 million, a 22% increase, year over year.
Adjusted gross margin held at 29% compared to the year ago quarter.
Cannabis gross profit increased 37% to $18.6 million from $13.5 million in the prior year quarter, while the gross margin percentage increased to 37% from 23%.
This was driven by our success in implementing numerous cost-savings programs, offset in part by our allocated overhead from intentionally reducing production, coupled with the revenue realized from our strategic alliance with HEXO in the current year and in inventory provision in the prior year.
Achieved $119.6 million in annualized cash cost-savings since the closing of the Tilray-Aphria transaction in May 2021, up from $108 million as of August 31, 2022.
Adjusted EBITDA of $11.7 million, marking the 15th consecutive quarter of positive adjusted EBITDA.
It’s hard to take anyone serious that thinks this scam is anything close to a “good” investment
More good news: Tilray Medical has received approval and verification from The Natural Health Science Foundation of its flagship product, Tilray Purified Oral Solution CBD100, to be used in clinical trials in Australia and New Zealand.
Details bit.ly/3T94yUq $TLRY
Tilray Medical expands its European footprint with market authorization to distribute Tilray branded medical cannabis in pharmacies across #Poland. Details bit.ly/3AC2TzP
$150 for me
My man Simon:
https://quantisnow.com/insight/3204184
Adjusted EBITDA of $11.5 million, marking the Company’s 13th consecutive quarter of positive Adjusted EBITDA
Saul Goodman would be proud!
1:33p ET 3/25/2022 - Benzinga
Tilray Whale Trades Spotted
Mentioned: TLRY
Someone with a lot of money to spend has taken a bearish stance on Tilray (NASDAQ:TLRY).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TLRY, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 15 options trades for Tilray.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 80%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $36,300, and 14, calls, for a total amount of $785,042..
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $6.5 to $25.0 for Tilray over the last 3 months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Tilray options trades today is 7478.54 with a total volume of 52,326.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Tilray's big money trades within a strike price range of $6.5 to $25.0 over the last 30 days.
Tilray Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
SymbolPUT/CALLTrade TypeSentimentExp. DateStrike PriceTotal Trade PriceOpen InterestVolume
TLRYCALLTRADEBEARISH04/14/22$8.00$250.0K7.7K13.8K
TLRYCALLSWEEPBULLISH04/01/22$7.00$66.3K10.2K159
TLRYCALLTRADEBEARISH01/19/24$15.00$57.8K3.4K783
TLRYCALLSWEEPBULLISH04/01/22$7.50$56.9K9.5K8.2K
TLRYCALLSWEEPBEARISH04/01/22$9.50$56.3K3262.9K
Where Is Tilray Standing Right Now?
With a volume of 186,889,580, the price of TLRY is up 11.69% at $7.79.
RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
Next earnings are expected to be released in 11 days.
What The Experts Say On Tilray:
Canaccord Genuity upgraded its action to Buy with a price target of $9
Piper Sandler has decided to maintain their Neutral rating on Tilray, which currently sits at a price target of $6.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
7:00a ET 11/29/2021 - Dow Jones
Giant U.S. Pension Bought AMC, Snowflake, and Tilray. It sold Berkshire Hathaway. -- Barrons.com
Mentioned: AMC BRK.A BRK.B SNOW TLRY
Ed Lin
The second-largest public pension by assets in the U.S. increased its stake in one of the year's most-volatile stocks, initiated a position in a marijuana grower, and trimmed its exposure to Warren Buffett.
The California State Teachers' Retirement System bought more shares of movie-theater chain AMC Entertainment Holdings (ticker: AMC) and analytics-software firm Snowflake ( SNOW), acquired shares of the cannabis producer Tilray (TLRY), and reduced its holdings in Berkshire Hathaway ( BRKb), Buffett's investment juggernaut. Calstrs, as the pension is known, disclosed the stock trades, among others, in a form it filed with the Securities and Exchange Commission.
Calstrs said it doesn't comment on its holdings or on individual investment managers. The pension managed $321.9 billion in assets as of Oct. 31 .
Calstrs bought 133,512 more shares of AMC to end the third quarter with 689,917 shares. AMC's stock price rocketed nearly 19-fold in the first nine months of the year, and so far in the fourth quarter shares are down 1%. For comparison, the S&P 500 index rose 15% in the first nine months, and has gained 6.7% so far in the fourth quarter.
AMC stock caught fire during the meme-stock frenzy early in the year, when small investors communicating via social media bought shares of beaten-down companies in hopes of triggering gains that would force people who had bet against those stocks to buy in order to close their bets. The trend led to a surge in volatility that prompted the Federal Reserve to warn this month that meme-stock related market swings could be a risk to the financial system. AMC's third-quarter results were better than expected, and the chain is now accepting cryptocurrencies for online payments.
The pension bought 347,900 Tilray shares in the third quarter; at the end of the second, it hadn't owned any. Tilray stock rose 37% in the first nine months of the year, and so far in the fourth quarter shares are down 6.4%.
In early October, Tilray reported a wider-than-expected loss for the fiscal first quarter. Recent legislative proposals, including one that would decriminalize pot at the federal level have lifted Tilray and its peers. The legal-pot sector, however, saw layoffs during the Covid-19 pandemic.
Snowflake stock rose 7.5% in the first nine months of the year, and so far in the fourth quarter shares have gained 20%. The gain could have been bigger, but Snowflake and other cloud-software peers slipped after President Joe Biden nominated Federal Reserve Board Chair Jerome Powell to another four-year term. Interest rates rose in the wake of the nomination, tempering enthusiasm for richly valued, high-growth stocks.
The company reported a mixed second quarter in August, and Snowflake will report its third quarter after the market close on Dec. 1.
Calstrs bought 119,934 additional Snowflake shares to end the third quarter with 328,801 shares.
The pension sold 511,630 class B shares of Berkshire Hathaway to end the third quarter with 2.9 million shares of Buffett's firm. Shares rose 18% in the first nine months of the year, and so far in the fourth quarter they have gained 3.7%.
Berkshire Hathaway disclosed that it had a record $149 billion in cash at the end of September. Buffett and John Malone -- two billionaires skilled in tax-efficient transactions -- recently did a stock swap. During the third quarter, Berkshire Hathaway itself sold Big Pharma stock.
Inside Scoop is a regular Barron's feature covering stock transactions by corporate executives and board members -- so-called insiders -- as well as large shareholders, politicians, and other prominent figures. Due to their insider status, these investors are required to disclose stock trades with the Securities and Exchange Commission or other regulatory groups.
Thanks John $$$Tilray$$$
CC Pharma’s purchase would go down has one of the best investments Aphria (at the time) made. $$$TILRAY$$$
Here is 2019 article regarding awards Aphria received under Simon before COVID. Quality products
https://www.prnewswire.com/news-releases/aphria-inc-brands-win-top-honours-at-2019-canadian-cannabis-awards-300955574.html
With two state-of-the-art, GMP-certified cannabis facilities in Portugal and Germany, Tilray is ready to service patients and consumers in Europe and around the world. #AWorldofWellbeing $TLRY pic.twitter.com/sIXpoTXyNt
— Tilray Brands (@tilray) November 19, 2021
“With two state-of-the-art, GMP-certified cannabis facilities in Portugal and Germany, Tilray is ready to service patients and consumers in Europe and around the world” Simon Retweet
Back up we go, they can only manipulate it for so long $$$TILRAY$$
BERLIN (Reuters) - Legalising cannabis could bring Germany annual tax revenues and cost savings of about 4.7 billion euros ($5.34 billion) and create 27,000 new jobs, a survey said on Tuesday as politicians thrash out rules for the budding sector.
Chancellor-in-waiting Olaf Scholz and his centre-left Social Democrats (SPD) are in talks with the environmentalist, pro-spending Greens and the libertarian, business-friendly Free Democrats (FDP) to build a three-way coalition.
Negotiators for the SPD, Greens and FDP are still working out details of their coalition deal, including rules under which the sale and use of recreational cannabis would be allowed and regulated in Europe's largest economy.
The survey by the Institute for Competition Economics (DICE) at the Heinrich Heine University in Duesseldorf, and commissioned by the German hemp association, found that legalising cannabis could lead to additional tax revenues of about 3.4 billion euros per year.
At the same time, it could bring cost savings in the police and judicial system of 1.3 billion euros per year while creating tens of thousands of jobs in the cannabis economy.
Legalising cannabis in Germany would give a boost to a ballooning European market that is expected to be worth more than 3 billion euros in annual revenue by 2025, up from about 400 million euros this year, according to the European Cannabis Report by research firm Prohibition Partners.
The use of cannabis for medicinal purposes has been legal in Germany since 2017.
($1 = 0.8804 euros)
(Reporting by Michael Nienaber; Editing by Miranda Murray and Pravin Char)
Tilray invites all stockholders of record to attend the Annual Meeting of Stockholders which will be held on November 22, 2021 at 11:00 a.m. EST. Details bit.ly/2YORLiG $TLRY
Good morning Tilray $$$$
Power of Simon compels you
Germany’s likely next ruling coalition is closing in on a deal to legalize cannabis for recreational use, the strongest signal yet that long-awaited growth of Europe’s marijuana market is gaining traction.
Negotiators for the Social Democrats, Greens and pro-business Free Democrats are hammering out the details, including conditions under which the sale and use of recreational cannabis would be allowed and regulated, according to people familiar with the talks, who asked not to be identified because the discussions are private.
They’re part of wider negotiations on forming a new government, with the three parties targeting early December for a new administration to take office under Social Democrat Olaf Scholz.
No final decision on cannabis has been made and the outcome could still change, the people said. Spokespeople for the Greens and SPD declined to comment on any aspect of the coalition talks. A spokesperson for the FDP didn’t immediately respond to a request for comment on the cannabis plan.
An agreement on its legalization wouldn’t be overly surprising. The likely coalition partners have been more open to the idea than Angela Merkel’s Christian Democrats, who have been in power since 2005.
The move would give a boost to a European market that is projected to be worth 3.2 billion euros (US$3.7 billion) by 2025, up from 403 million euros at the end of this year, according to the European Cannabis Report by research firm Prohibition Partners.
The step could bring in fresh tax revenue and be a boon for U.S. and Canadian cannabis firms as well as a nascent German industry that includes firms such as Cantourage GmbH and Synbiotic SE.
Many cannabis growers already have a foot in Europe’s door through medical businesses and have been positioning themselves to benefit from a bigger recreational market. Curaleaf Holdings Inc., the U.S.’s largest multistate operator, earlier this year bought Emmac Life Sciences Ltd., poising it to capitalize. Curaleaf Chairman Boris Jordan also has a stake in Frankfurt-based startup Algea Care.
Tilray Inc. has a facility in Portugal that it says aims to ship marijuana across Europe, and it has been touting its merger with U.S. company Aphria Inc. Other Canadian operators, such as Aurora Cannabis Inc. and Canopy Growth Corp., also currently serve the German medical market.
The United Nations late last year decided to remove cannabis from its list of hard drugs, followed by the European Commission’s categorization of cannabidiol, an active ingredient derived from the hemp plant, as food rather than narcotic.
Public opinion in Germany has also shifted toward legalization. In a survey at the end of October by the German Hemp Association, 49 per cent of respondents said they were in favor of legalizing cannabis, for example in specialty shops as in the U.S. and Canada, compared with 46 per cent who were still opposed. That’s the first time since 2014 that more people were in favor in the annual poll
“The path of the righteous man is beset on all sides….,,,” Simon 25:17
Simon on tv:
Simon just retweeted:
BREAKING: Which #ganja did $JPM greenlight? #Weed stocks' wild day: JPM tells brokerage clients they can only buy *certain* #cannibis names: CEO of @tilray Irwin Simon w/me EXCLSV 3pET, $TLRY spiking 13% right now. @ClamanCountdown
— Liz Claman (@LizClaman) November 8, 2021
I would not mind having a Sweetwater Hazy IPA beverage after good $$TILRAY$$ day.
Broken Coast products are top notch, won awards also.
-- SweetWater and RIFF Cannabis, a Leading Tilray Cannabis Brand, Launch the Ultimate Joint Effort with Sweetwater RIFF,
New Vodka Cocktail in a Can –
ATLANTA and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Tilray, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY),
today announced that two of its leading brands, SweetWater Brewing Company (“SweetWater”) and RIFF Cannabis (“RIFF”), have collaborated for the exclusive U.S. launch of SweetWater RIFF
-- SweetWater’s first ready-to-drink (RTD) cocktail and its inaugural entry into the spirits category. SweetWater RIFF brings a unique twist on RTD vodka sodas in two offerings: SweetWater RIFF Citrus and SweetWater RIFF Strawberry Mule.
“SweetWater’s entry into the spirits category reflects the essence of the SweetWater brand: original, compelling and enticing,” said Brian Miesieski, SweetWater’s Chief Marketing Officer. “SweetWater RIFF delivers a great-tasting ready-to-drink cocktail with a premium taste developed in partnership with RIFF’s own highly curated, expertly made approach. We are incredibly excited to expand and create something that is a great alternative to our incredible selection of beers and seltzers – and believe consumers will love it.”
“From day one, RIFF has been built on collaborations and creative product innovation,” added Bernie Yeung, Tilray’s SVP of Sales & Marketing. “Consistent with this approach, we are thrilled to harness the power of Sweetwater and RIFF, two of our leading brands, to launch Sweetwater RIFF. We are equally thrilled that the launch itself introduces U.S. consumers to RIFF, our creatively crafted cannabis brand that loves a joint effort. The SweetWater RIFF drinks are a true ‘RIFF’ on the classics and an elevated spin on consumer expectations.”
For those craving a premium, compelling, and authentic ready-to-drink cocktail, SweetWater RIFF drinks are crafted with vodka and real fruit juices. SweetWater RIFF Citrus is made with orange and lime juices and cut with coriander and sea salt for a unique and tasty twist, and SweetWater RIFF Strawberry Mule is tuned up with strawberry and lime juice with a hit of ginger for an extra flavor kick -- innovative flavor combinations that deliver a refreshing and great tasting drink for any occasion. SweetWater RIFF ready-to-drink cocktails are low calorie with only 105 calories each, 1 gram of carbs, 0.5 grams of natural sugar derived from fruit, and no added sugar or any cannabis or THC.
Now available in 6-pack 12 oz. slim cans – a first for SweetWater – SweetWater RIFF drinks are now rolling out across the U.S. in select grocery and liquor stores, as well as on-premise bars and restaurants. Stay tuned for more spirits-based cocktail launches coming soon!
$$TILRAY$$ is the way!
Cannabis stock burnout? @TimSeymour breaks down how trade limits on pot stocks could impact the group pic.twitter.com/8T7zi0KT6C
— CNBC's Fast Money (@CNBCFastMoney) November 3, 2021